Author

Laura Hagerty

Observed names: L. Hagerty, Laura L. Hagerty

Institution: ReveraGen BioPharma (United States)

Observed institutions: Muscular Dystrophy Association, Duke University, GlaxoSmithKline (United States), Duke Medical Center, ReveraGen BioPharma (United States)

ORCID: 0000-0001-6341-0697

Observed ORCID: 0000-0001-6341-0697

OpenAlex ID: A5073030567

ROCK1 Phosphorylates and Activates Zipper-interacting Protein Kinase

2006 · Laura Hagerty, Douglas H. Weitzel, et al. · Journal of Biological Chemistry · 90

Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study

2020 · Edward C. Smith, Laurie S. Conklin, et al. · PLoS Medicine · 87

Total-body creatine pool size and skeletal muscle mass determination by creatine-(methyl-d3) dilution in rats

2012 · Stephen A. Stimpson, Scott M. Turner, et al. · Journal of Applied Physiology · 75

Fluorescence Linked Enzyme Chemoproteomic Strategy for Discovery of a Potent and Selective DAPK1 and ZIPK Inhibitor

2013 · David A. Carlson, Aaron S. Franke, et al. · ACS Chemical Biology · 53

Maximizing the Benefit of Life-Saving Treatments for Pompe Disease, Spinal Muscular Atrophy, and Duchenne Muscular Dystrophy Through Newborn Screening: Essential Steps

2019 · Mei Baker, Robert Griggs, et al. · JAMA Neurology · 19

Cardiolipin profiles as a potential biomarker of mitochondrial health in diet‐induced obese mice subjected to exercise, diet‐restriction and ephedrine treatment

2014 · Catherine Faber, Zhaohai J. Zhu, et al. · Journal of Applied Toxicology · 15

Mineralocorticoid receptor antagonism of vamorolone: Evidence from LIONHEART and VISION-DMD clinical trials

2025 · Ana de Vera, Paula R Clemens, et al. · Steroids · 11

Preclinical efficacy of a gene therapy for CHKB-mediated muscular dystrophy

2026 · Mahtab Tavasoli, Mariam Alkandari, et al. · Molecular Therapy Advances · 1

Integrating Genetic Modifier Genotype With Serum Proteomics in Duchenne Muscular Dystrophy Clinical Trials Links LTBP4 Genetic Modifier to IL ‐23/ CD93 Pathways in Muscle

2026 · Utkarsh J. Dang, Yuan Fang, et al. · American Journal of Medical Genetics Part A

Prednisone, not vamorolone, suppresses novel serum bone and cartilage biomarkers associated with growth failure in children with Duchenne muscular dystrophy

2026 · Rebecca A. Tobin, Utkarsh J. Dang, et al. · Scientific Reports

Vamorolone: The First Dissociative Corticosteroid with Mineralocorticoid Antagonist Activity in Man: Evidence from LIONHEART and VBP15–004 Biomarkers

2026 · P. Clemens, A. de Vera, et al. · Neuropediatrics

Exposure-response of serum biomarkers to vamorolone, a dissociative corticosteroidal anti-inflammatory drug, in 4- to <7-year children

2025 · Swati Mummidivarpu, Utkarsh J. Dang, et al. · Steroids

Some functional improvements in placebo and Delandistrogene moxeparvovec-treated trial participants explained by increased corticosteroid dosing

2025 · Eric P. Hoffman, Paula R. Clemens, et al. · Journal of Neuromuscular Diseases

Incidence of spontaneously occurring elevation of fasting blood glucose and its association with increased sarcopenia and exercise capacity deficit in aging C57BL/6J mice (LB818)

2014 · W Wallace Harrington, Naphtali Milliken, et al. · The FASEB Journal

Delineating signal transduction pathways in smooth muscle through focused proteomics

2006 · Laura Hagerty, Timothy AJ Haystead · Expert Review of Proteomics

Works count: 15

Citation count: 351

H-index: 7

I10-index: 7